CRISPR screen reveals modifiers of rAAV production including known rAAV infection genes playing an unexpected role in vector production

Recombinant adeno-associated virus (rAAV) vectors are an effective and well-established tool in the growing gene therapy field, with five U.S. Food and Drug Administration-approved AAV-mediated gene therapies already on the market and numerous more in clinical trials. However, manufacturing rAAV vec...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Emily E. O’Driscoll, Sakshi Arora, Jonathan F. Lang, Beverly L. Davidson, Ophir Shalem
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2025-03-01
Saila:	Molecular Therapy: Methods & Clinical Development
Gaiak:	AAV rAAV2 gene therapy rAAV production CRISPR screens
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S2329050125000038
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!